Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.
As it re-thinks its business model, Big Pharma has revamped its playbook on many fronts, entering previously unappealing niche markets that draw it closer to customers.
But few pharma companies have ventured far into critical care, a highly specialized area that seems, on the surface, to...